ID
IDTA.US Identa Corp
- Market cap
- USD 1.01M
- P/E
- 11.5x
- P/B
- 0.77x
- ROE
- -2.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is IDTA.US undervalued?
Graham numberIDTA.US trades 37.2% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Identa Corp fundamental analysis
No fundamental analysis for Identa Corp yet.
Identa Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Identa Corp
IDenta Corp. operates as a detection and forensic science company. The company offers drug, and explosives testing kits; aero chamber sniffer; forensic; and urine, and saliva drug testing products. It provides its solutions to law enforcement, military, and government agencies, as well as other organizations that deal in fighting illicit drugs and terrorist threats. The company has operations in Israel, the United States, the United Nations, DEA, Germany, France, Italy, Spai…
Full company profileIdenta Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Identa Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 412K | 415K | 827K | 1.01M | 1.45M | 1.39M | 1.34M | 1.05M | 1.46M | 1.34M | 2.07M |
| Gross Profit | 157K | 292K | 593K | 625K | 874K | 1.01M | 983K | 663K | 753K | 687K | 929K |
| Operating Income | -348K | -149K | 148K | 103K | 356K | 214K | 125K | -1.50K | 306K | 185K | 241K |
| EBITDA | - | -161K | 155K | 80.1K | 375K | 136K | 200K | 71.6K | 289K | 129K | 135K |
| Net Income | -451K | -172K | 143K | 65.5K | 354K | 69.2K | 163K | 14.6K | 258K | 99.0K | -33.7K |
| EPS | - | -0.04 | 0.04 | 0.02 | 0.09 | 0.02 | 0.04 | 0.00 | 0.06 | 0.02 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 558K | 449K | 575K | 678K | 1.06M | 1.23M | 1.62M | 1.53M | 1.66M | 1.92M | 2.38M |
| Total Liabilities | 559K | 611K | 592K | 695K | 720K | 799K | 1.16M | 1.01M | 921K | 1.04M | 1.08M |
| Shareholders' Equity | -1.68K | -163K | -16.7K | -16.9K | 340K | 430K | 460K | 516K | 742K | 879K | 1.30M |
| Cash & Short-term Investments | 128K | 106K | 196K | 225K | 541K | 347K | 434K | 264K | 414K | 379K | 670K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -241K | -75.3K | 149K | -14.7K | 432K | -88.9K | 94.3K | -138K | 562K | 56.9K | -38.4K |
| Capital Expenditure | 13.7K | 13.7K | 12.7K | 12.3K | 53.2K | 133K | 32.7K | 14.3K | 6.04K | 16.7K | 35.3K |
| Free Cash Flow | - | -89.0K | 136K | -27.0K | 379K | -222K | 61.6K | -152K | 556K | 40.3K | -73.7K |
| Ratios | |||||||||||
| ROE | - | - | - | - | 104.1% | 16.1% | 35.4% | 2.8% | 34.8% | 11.3% | -2.6% |
| ROA | -80.8% | -38.2% | 24.8% | 9.7% | 33.4% | 5.6% | 10.0% | 1.0% | 15.5% | 5.2% | -1.4% |
| Net Profit Margin | -109.2% | -41.3% | 17.3% | 6.5% | 24.4% | 5.0% | 12.2% | 1.4% | 17.7% | 7.4% | -1.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Identa Corp dividends
Identa Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4000 on Jun 20, 2017.
Who owns Identa Corp
Ownership data of Identa Corp is not available yet.
Identa Corp company profile
- Company name
- Identa Corp
- Ticker
- IDTA.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- December
- Address
- 120 Bethlehem Road, Jerusalem, Israel, 93420
- Phone
- 972 2 587 2220
- Website
- identa-corp.com
About Identa Corp
IDenta Corp. operates as a detection and forensic science company. The company offers drug, and explosives testing kits; aero chamber sniffer; forensic; and urine, and saliva drug testing products. It provides its solutions to law enforcement, military, and government agencies, as well as other organizations that deal in fighting illicit drugs and terrorist threats. The company has operations in Israel, the United States, the United Nations, DEA, Germany, France, Italy, Spain, Indonesia, Brazil, Mexico, South Africa, Australia, Canada, and internationally. IDenta Corp. was founded in 2002 and is headquartered in Jerusalem, Israel.
Identa Corp management
3- Mr. Amichai GlattsteinCEO & Director
- Mr. Baruch GlattsteinCo-Founder, CTO & Chief Science Officer
- Mr. Mishael SpitzerChief Operating Officer